Marizyme Inc. (MRZM)
OTCQB OTCQB Primary Summary
Marizyme Inc. (MRZM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Marizyme Inc. ever had a stock split?
Marizyme Inc. Profile
| Biotechnology Industry | Healthcare Sector | David L. Barthel CEO | OTCQB Exchange | 570372102 CUSIP |
| US Country | 13 Employees | - Last Dividend | 27 Jul 2018 Last Split | - IPO Date |
Overview
Marizyme, Inc. is a multi-technology biomedical company focused on the development and commercialization of medical technologies aimed at improving patient health. This company takes a diverse approach, targeting multiple areas of medical care through its innovative products. Originally known as GBS Enterprises Incorporated, the company underwent a rebranding to Marizyme, Inc. in March 2018, marking a new phase in its commitment to medical science and patient care. With its establishment in 2007 and headquarters in Jupiter, Florida, Marizyme has been dedicated to bringing forward technologies that offer significant therapeutic and diagnostic benefits to both the medical community and the patients it serves.
Products and Services
- DuraGraft
- MATLOC
- Krillase
- MAR-FG-001
A novel single-use intraoperative vascular graft treatment designed to protect against ischemic injury and reduce the incidence and complications of graft failure. DuraGraft provides a unique solution for patients undergoing surgical procedures that involve vascular grafts, aiming to improve outcomes and enhance the long-term success of these surgeries.
This advanced platform represents a leap in point-of-care diagnostic capabilities, offering a lab-on-chip digital screening and diagnostic device specifically developed for the quantitative assessment of chronic kidney disease. MATLOC simplifies the monitoring and management of this widespread condition, potentially transforming how kidney health is approached in clinical settings.
A potent protein enzyme with a significant therapeutic potential in wound healing, thrombosis, and pet health. Krillase is being developed to address a variety of medical needs, from enhancing the healing processes of wounds to offering new avenues in the treatment and management of thrombotic diseases. Its application in pet health further underscores Marizyme's commitment to broadening its impact across different areas of health and wellness.
A cutting-edge fat grafting technology under development for use in fat grafting procedures. MAR-FG-001 is aimed at improving the efficiency and outcomes of these procedures, offering new possibilities for both patients and practitioners in the field of reconstructive surgery. By enhancing the viability and integration of fat grafts, this technology could significantly advance therapeutic and aesthetic results.
